GAPDH-IN-1

• Description :

  GAPDH-IN-1 (Compound F8) is a GAPDH inhibitor (IC50 of 39.31 μM for GAPDH enzymatic activity) . GAPDH-IN-1 forms a covalent adduct with an aspartic acid in the active site to displace NAD+, a cofactor of the enzyme, with concomitant enhancement of the cysteine-reactive probe reaction with the catalytic cysteine[1].

• CAS Number :

  [252212-58-1]

• UNSPSC :

  12352005

• Target :

  Endogenous Metabolite

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Metabolism-protein/nucleotide metabolism

• Field of Research :

  Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/gapdh-in-1.html

• Purity :

  98.1

• Smiles :

  C1(C2=CC(OCC3OC3)=CC=C2)=NN=C(C4=CC(OCC5OC5)=CC=C4)O1

• Molecular Formula :

  C20H18N2O5

• Molecular Weight :

  366.37

• References & Citations :

  [1]Jung Y, et al. Discovery of Non-Cysteine-Targeting Covalent Inhibitors by Activity-Based Proteomic Screening with a Cysteine-Reactive Probe. ACS Chem Biol. 2022 Feb 18;17 (2) :340-347.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported